Geron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Geron and other ETFs, options, and stocks.

About GERN

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. 

CEO
Harout Semerjian
CEOHarout Semerjian
Employees
258
Employees258
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1990
Founded1990
Employees
258
Employees258

GERN Key Statistics

Market cap
888.51M
Market cap888.51M
Price-Earnings ratio
-13.33
Price-Earnings ratio-13.33
Dividend yield
Dividend yield
Average volume
13.14M
Average volume13.14M
High today
$1.53
High today$1.53
Low today
$1.38
Low today$1.38
Open price
$1.50
Open price$1.50
Volume
12.75M
Volume12.75M
52 Week high
$2.01
52 Week high$2.01
52 Week low
$1.04
52 Week low$1.04

Stock Snapshot

With a market cap of 888.51M, Geron(GERN) trades at $1.40. The stock has a price-to-earnings ratio of -13.33.

On 2026-05-10, Geron(GERN) stock traded between a low of $1.38 and a high of $1.53. Shares are currently priced at $1.40, which is +1.4% above the low and -8.5% below the high.

The Geron(GERN)'s current trading volume is 12.75M, compared to an average daily volume of 13.14M.

In the last year, Geron(GERN) shares hit a 52-week high of $2.01 and a 52-week low of $1.04.

In the last year, Geron(GERN) shares hit a 52-week high of $2.01 and a 52-week low of $1.04.

GERN News

Simply Wall St 1d
Assessing Geron Valuation After Q1 2026 Earnings Beat And RYTELO Growth Progress

Geron (GERN) is back in focus after its Q1 2026 earnings, where revenue and loss per share came in ahead of expectations, supported by RYTELO growth, reiterated...

Assessing Geron Valuation After Q1 2026 Earnings Beat And RYTELO Growth Progress
Simply Wall St 2d
Can Geron’s Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential?

Geron Corporation has already reported first-quarter 2026 results, with revenue rising to US$51.84 million from US$39.6 million and net loss narrowing to US$3.6...

Can Geron’s Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential?
TipRanks 3d
Geron Earnings Call Highlights RYTELO-Driven Momentum

Geron Corporation ((GERN)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and p...

Analyst ratings

67%

of 6 ratings
Buy
66.7%
Hold
16.7%
Sell
16.7%

More GERN News

The Motley Fool 3d
Geron Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, May 6, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Harout Semerjian Chief Commercial Officer — Ahme...

Geron Q1 2026 Earnings Call Transcript
TipRanks 3d
Geron reports Q1 EPS (1c), consensus (2c)

Reports Q1 revenue $51.84M, consensus $50.59M. “We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strateg...

People also own

Based on the portfolios of people who own GERN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.